Michael Martin, Ph.D.

Dr. Michael Martin is the Global Head of Takeda Ventures, Inc. (TVI) and he is based in San Diego, CA. His professional background includes venture capital, pharma business development and broad R&D experience with an integral role in the discovery and preclinical/clinical development of 17 innovative investigational drugs and 2 commercial products. Prior to joining TVI, Dr. Martin was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for sourcing and transacting technologies and early stage pipeline programs. Dr. Martin joined Takeda in January 2012 through the acquisition of Intellikine where he was Vice President of Preclinical Development. Additionally, he has held executive and senior management and scientific positions with TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals, and Monsanto Corporation. Dr. Martin earned his doctorate in Medicinal Chemistry from the University of Illinois and holds a M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.